Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

NCT ID: NCT03315494

Last Updated: 2017-10-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-09-22
• Study Completion Date: 2016-12-21

Brief Summary

This double-blind, placebo-controlled, multiple ascending dose study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of SKI-O-703 in healthy volunteers.

Detailed Description

This is a double-blind, placebo-controlled study in healthy adult volunteers, to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses of SKI-O-703. A total of 24 subjects are planned to participate in 3 cohorts (8 subjects each). In each cohort, 6 subjects will be randomly assigned to receive SKI-O-703 and 2 subjects will be randomly assigned to matching placebo. Dosing will be initiated with a 200 mg once daily (QD) dose cohort and escalated to 400 mg QD, under fasting conditions, for 7 days. In the third cohort, a 200 mg twice daily (BID) dose will be studied for 7 days. Evening dosing will occur 12 hours after the morning dose and will be preceded by fasting for at least 3 hours. After all 8 subjects in each cohort have received the study drug and been monitored, the decision to escalate to the next dose cohort will be made.

Conditions

Arthritis, Rheumatoid

Keywords

rheumatoid arthritis; healthy volunteers; moderate to severe

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

SKI-O-703 200 mg (once daily)

SKI-O-703 capsule (1 x 200 mg)

Group Type: EXPERIMENTAL

SKI-O-703 capsule

Intervention Type: DRUG

SKI-O-703 200 mg capsule with no inactive excipients.

SKI-O-703 400 mg (once daily)

SKI-O-703 capsule (2 x 200 mg, once daily)

Group Type: EXPERIMENTAL

SKI-O-703 capsule

Intervention Type: DRUG

SKI-O-703 200 mg capsule with no inactive excipients.

SKI-O-703 200 mg (twice daily)

SKI-O-703 capsule (1 x 200 mg twice daily)

Group Type: EXPERIMENTAL

SKI-O-703 capsule

Intervention Type: DRUG

SKI-O-703 200 mg capsule with no inactive excipients.

Placebo

Placebo capsule

Group Type: PLACEBO_COMPARATOR

Placebo capsule

Intervention Type: DRUG

Placebo 180 mg capsule filled with microcrystalline cellulose.

Interventions

SKI-O-703 capsule

SKI-O-703 200 mg capsule with no inactive excipients.

Intervention Type: DRUG

Placebo capsule

Placebo 180 mg capsule filled with microcrystalline cellulose.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Willing and able to provide written informed consent for participation prior to completing any study procedures.
• Considered by investigator to be in good health, as judged by absence of clinically significant diseases and clinically significant abnormal values as determined by detailed medical history review, complete physical examination, and clinical laboratory evaluations.
• Male subjects and female subjects of non-childbearing potential 18-55 years old, inclusive, at time of screening.
• Females of non-childbearing potential are those who have been surgically sterile for at least 6 months or who have been postmenopausal for at least 2 years and have follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
• Male subjects agree to use a condom with spermicide or to abstain from sexual intercourse for 90 days after dosing.
• Male subjects must agree not to donate sperm for 90 days after dosing.
• Female subjects must have negative pregnancy tests at screening and on Day -1.
• Body mass index between 18.0 and 30.0 kg/m2, inclusive, and body weight of ≥ 50 kg.
• Able to understand the study and any risks of participation and able to communicate with the investigator.

Exclusion Criteria

• History of any clinically significant disease or disorder that may put the subject at risk due to study participation, impact the subject's ability to participate in the study, or influence the study results.
• History or presence of any gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
• Any surgical or medical condition that could possibly affect drug absorption, distribution, metabolism, and excretion (e.g. bariatric procedure).
• Any medical/surgical procedure or trauma within 4 weeks prior to Day -1 as determined by the investigator.
• Any clinically significant infection within 3 months prior to Day -1 as determined by the investigator.
• Any of the following abnormal laboratory values upon repeat testing at Screening or Check-in (Day -1):

1. Hemoglobin < lower limit of normal (LLN),

2. Platelet count <LLN,

3. Absolute neutrophil count <LLN or >upper limit of normal (ULN),

4. Alanine aminotransferase or aspartate aminotransferase >ULN,

5. Creatinine or blood urea nitrogen >ULN, or

6. Any other clinically significant, in the opinion of the investigator, abnormal laboratory result.

• Use of concomitant medications from 30 days or 5 half-lives prior to Day -1 (whichever is longer) through completion of the End of Study (EOS) visit, including prescription medications, nutritional supplements, herbal remedies, and over-the-counter medications (note: use of vitamin supplements should be stopped at least 7 days prior to Screening through completion of the EOS visit).
• Receipt of any investigational medication within 30 days or 5 half-lives prior to Day -1, whichever is longer.
• Use of tobacco or nicotine-containing products within 30 days prior to Day -1 through the EOS visit.
• Use of CYP3A inducers and inhibitors (including St. John's wort) within 30 days prior to dosing.
• Intake of food or beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), or charbroiled meats within 1 week prior to dosing.
• History of substance abuse, drug addiction, or alcoholism.
• Positive urine drug or urine alcohol test at Screening or Day -1 or unable to abstain from alcohol from 72 hours prior to study entry through the EOS visit.
• Unable to abstain from caffeine- and xanthine-containing products from 72 hours prior to dosing through discharge from the study center.
• Female subjects who are pregnant or lactating or have a positive pregnancy test at Screening or Day -1.
• Positive result at Screening for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody or positive result for hepatitis B core antibody with a negative result for hepatitis B surface antigen.
• Recent (within the past 5 years) history of malignancy, except successfully treated basal cell carcinoma.
• High blood pressure, defined as >140 mm Hg systolic blood pressure or >90 mm Hg diastolic blood pressure upon repeat confirmation (repeated up to 4 times).
• Cardiac arrhythmias or clinically significant electrocardiogram (ECG) findings.
• Corrected QT interval >450 milliseconds or deemed clinically significant by the investigator (may be repeated for confirmation).
• Family history of long QT syndrome.
• Blood loss or blood donation >450 mL within 4 weeks prior to study drug dosing.
• History of sensitivity to drugs with chemical similarity to the study medication, its components, or the excipients.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

PPD Development, LP

INDUSTRY

Sponsor Role: collaborator

Oscotec Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

PPD Development, LP

Austin, Texas, United States

Countries

United States

Other Identifiers

OSCO-P1202

Identifier Type: -

Identifier Source: org_study_id